This website is for Israeli Healthcare Professionals only.

PRODUODOPA Has a Well-studied Safety Profile.1

Most Frequent Adverse Reactions1

The most frequent adverse reactions (≥10%) were:1

Infusion site events (infusion site erythema, infusion site cellulitis, infusion site nodule,
infusion site pain, infusion site oedema, infusion site reaction, and infusion site infection).
Hallucinations
Falls
Anxiety

Most Frequent Adverse Reactions1

The most frequent adverse reactions (≥10%) were:1

Infusion site events (infusion site erythema, infusion site cellulitis, infusion site nodule, infusion site pain, infusion site oedema, infusion site reaction, and infusion site infection).
Hallucinations
Falls
Anxiety

Infusion Site Events:1

The majority of infusion site events were non-serious, mild or moderate in severity, and resolved
spontaneously, or with treatment with antibiotics and/or incision and drainage.
Three subjects with infusion site infections had a complication of sepsis resulting in hospitalization.

Infusion Site Events:1

The majority of infusion site events were non-serious, mild or moderate in severity, and resolved spontaneously, or with treatment with antibiotics and/or incision and drainage.
Three subjects with infusion site infections had a complication of sepsis resulting in hospitalization.

Produodopa Was Generally Safe.
The Majority of AEs Reported Were Non-Serious and Mild/Moderate.

The most common AEs of special interest were related to the infusion site being infusion site erythema, oedema, nodules, pain, cellulitis and abscess the most frequent ones1,3.

Among the subjects that suffered from hallucinations during the clinical trials, only 5.3% and 1.4% discontinued the study drug in 52 weeks & 12 weeks studies trials, respectively1,3.

Weight loss events were non-serious and mild or moderate in severity1,3.
There were no discontinuations due to polyneuropathy on the clinical trials1,3.

AE: Adverse Event; TEAE: Treatment Emergent Adverse Event.

Adverse reactions reported in all Phase 3 studies in patients exposed to PRODUODOPA (379 patients with total exposure of 414.3 person-years, 230 subjects exposed for ≥6 months, 204 subjects exposed for ≥12 months) or data from DUODOPA (levodopa/carbidopa intestinal gel) based on treatment emergent frequencies, regardless of causality assigned.1

System Organ Class

Frequency

Adverse Reactions

Infections and infestations

Very common (≥1/10)

Infusion site cellulitis
Infusion site infection
Urinary tract infection†

Common (≥1/100 to <1/10)*

Infusion site abscess

Blood and lymphatic system disorders

Common (≥1/100 to <1/10)

Anaemia†
Uncommon (≥1/1,000 to <1/100)Leukopenia†
Thrombocytopenia†
Immune system disorder

Not known

Anaphylactic reaction†‖

Metabolism and nutrition disorders

Common (≥1/100 to <1/10)

Decreased appetite

Psychiatric disorders

Very common (≥1/10)

Anxiety
Depression
Hallucination‡
Common (≥1/100 to <1/10)Abnormal dreams†
Agitation†
Confusional state
Delusion
Impulse control disorder
Insomnia
Paranoia
Psychotic disorder
Sleep attacks†
Sleep disorder†
Suicidal ideation
Uncommon (≥1/1,000 to <1/100)Completed suicide†
Dementia†
Disorientation†
Dopamine dysregulation syndrome
Euphoric mood†
Fear†
Libido increased†
Nightmare†
Suicide attempt†
Rare (≥1/10,000 to <1/1,000)Abnormal thinking†

Nervous system disorders

Common (≥1/100 to <1/10)Cognitive disorder
Dizziness
Dizziness postural
Dyskinesia
Dystonia
Headache
Hypoaesthesia
On and off phenomenon
Paraesthesia
Polyneuropathy§
Somnolence
Syncope
Tremor†
Uncommon (≥1/1,000 to <1/100)Ataxia†
Convulsion†
Gait disturbance†

Eye disorders

Uncommon (≥1/1,000 to <1/100)

Angle closure glaucoma†
Blepharospasm†
Diplopia†
Optic ischaemic neuropathy†
Vision blurred†

Cardiac disorders

Common (≥1/100 to <1/10)

Heart rate irregular†

Uncommon (≥1/1,000 to <1/100)

Palpitations

Vascular disorders

Common (≥1/100 to <1/10)

Hypertension
Hypotension
Orthostatic hypotension

Uncommon (≥1/1,000 to <1/100)

Phlebitis†

Respiratory, thoracic, and mediastinal disorders

Common (≥1/100 to <1/10)

Dyspnoea
Oropharyngeal pain†

Uncommon (≥1/1,000 to <1/100)

Dysphonia†

Rare (≥1/10,000 to <1/1,000)

Respiration abnormal†

Gastrointestinal disorders

Common (≥1/100 to <1/10)

Abdominal distension†
Abdominal pain
Constipation
Diarrhoea
Dry mouth
Dysgeusia†
Dyspepsia†
Dysphagia†
Flatulence†
Nausea
Vomiting
Uncommon (≥1/1,000 to <1/100)Salivary hypersecretion†
Rare (≥1/10,000 to <1/1,000)Bruxism†
Saliva discolouration†
Glossodynia†
Hiccups†

Skin and subcutaneous tissue disorders

Common (≥1/100 to <1/10)

Dermatitis contact†
Hyperhidrosis†
Pruritus
Rash
Uncommon (≥1/1,000 to <1/100)Alopecia†
Erythema†
Urticaria†
Rare (≥1/10,000 to <1/1,000)Sweat discolouration†
Malignant melanoma†

Musculoskeletal and connective tissue disorders

Common (≥1/100 to <1/10)

Muscle spasms
Neck pain†

Renal and urinary disorders

Common (≥1/100 to <1/10)

Urinary incontinence
Urinary retention
Uncommon (≥1/1,000 to <1/100)Chromaturia†
Rare (≥1/10,000 to <1/1,000)Priapism†

General disorders and administration site conditions

Very common (≥1/10)

Infusion site erythema
Infusion site reaction
Infusion site nodule
Infusion site oedema
Infusion site pain
Common (≥1/100 to <1/10)*Asthenia
Fatigue
Infusion site bruising
Infusion site exfoliation
Infusion site extravasation
Infusion site haematoma
Infusion site haemorrhage
Infusion site induration
Infusion site inflammation
Infusion site irritation
Infusion site mass
Infusion site papule
Infusion site pruritus
Infusion site rash
Infusion site swelling
Malaise
Oedema peripheral
Pain†
Uncommon (≥1/1,000 to <1/100)Chest pain

Investigations

Common (≥1/100 to <1/10)

Amino acid level increased (Methylmalonic acid increased)†
Blood homocysteine level increased†
Vitamin B6 decreased
Vitamin B12 deficiency†
Weight decreased
Weight increased†

Injury, poisoning, and procedural complications

Very common (≥1/10)

Fall

*Common adverse reactions pertaining to infusion site events included if ≥2%. †These adverse reactions were identified with DUODOPA intestinal gel as drug-related events. However, these events were not considered adverse reactions for PRODUODOPA. ‡Hallucination includes hallucination, hallucination  visual, hallucination auditory, hallucination olfactory, hallucinations tactile, and hallucinations mixed. §Polyneuropathy includes neuropathy peripheral, polyneuropathy, decreased vibratory sense, peripheral sensory neuropathy, sensory disturbance, and sensory loss. ‖Based on post-marketing data.

References

  1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) prescribing information.
  2. Soileau MJ, et al. Lancet Neurol. 2022;21:1099–1109.
  3.  Aldred J, et al. Neurol Ther. 2023 Aug 26. doi: 10.1007/5. s40120-023-00533.

IL-PRODD-260063 | June 2026

As part of ABBVIE CARE Produodopa patient support program,
a professional call center is available: 

Sunday through Thursday
8:00-17:00

052-8113004